Prabaha007 (Talk | contribs) |
Prabaha007 (Talk | contribs) |
||
(5 intermediate revisions by the same user not shown) | |||
Line 66: | Line 66: | ||
<li class="active hvr-underline-from-left"><a href="https://2016.igem.org/Team:IISc_Bangalore">Home</a></li> | <li class="active hvr-underline-from-left"><a href="https://2016.igem.org/Team:IISc_Bangalore">Home</a></li> | ||
<li class="hvr-underline-from-left"><a href="https://2016.igem.org/Team:IISc_Bangalore/Team">Team</a></li> | <li class="hvr-underline-from-left"><a href="https://2016.igem.org/Team:IISc_Bangalore/Team">Team</a></li> | ||
− | + | ||
<li class="dropdown"><a class="dropdown-toggle" data-toggle="dropdown" href="#">Project </a> | <li class="dropdown"><a class="dropdown-toggle" data-toggle="dropdown" href="#">Project </a> | ||
Line 73: | Line 73: | ||
<li><a href="https://2016.igem.org/Team:IISc_Bangalore/Experiments">Experiments</a></li> | <li><a href="https://2016.igem.org/Team:IISc_Bangalore/Experiments">Experiments</a></li> | ||
<li><a href="https://2016.igem.org/Team:IISc_Bangalore/Results">Results</a></li> | <li><a href="https://2016.igem.org/Team:IISc_Bangalore/Results">Results</a></li> | ||
+ | <li><a href="https://2016.igem.org/Team:IISc_Bangalore/Notebook">Notebook</a></li> | ||
+ | <li><a href="https://2016.igem.org/Team:IISc_Bangalore/Safety">Safety</a></li> | ||
</ul> | </ul> | ||
</li> | </li> | ||
− | + | ||
<li class="hvr-underline-from-left"><a href="https://2016.igem.org/Team:IISc_Bangalore/Parts">Parts</a></li> | <li class="hvr-underline-from-left"><a href="https://2016.igem.org/Team:IISc_Bangalore/Parts">Parts</a></li> | ||
− | + | ||
<li class="hvr-underline-from-left"><a href="https://2016.igem.org/Team:IISc_Bangalore/Collaborations">Collaborations</a></li> | <li class="hvr-underline-from-left"><a href="https://2016.igem.org/Team:IISc_Bangalore/Collaborations">Collaborations</a></li> | ||
<li class="hvr-underline-from-left"><a href="https://2016.igem.org/Team:IISc_Bangalore/Attributions">Attributions</a></li> | <li class="hvr-underline-from-left"><a href="https://2016.igem.org/Team:IISc_Bangalore/Attributions">Attributions</a></li> | ||
Line 91: | Line 93: | ||
<li><a href="https://2016.igem.org/Team:IISc_Bangalore/Entrepreneurship">Entrepreneurship</a></li> | <li><a href="https://2016.igem.org/Team:IISc_Bangalore/Entrepreneurship">Entrepreneurship</a></li> | ||
<li><a href="https://2016.igem.org/Team:IISc_Bangalore/Design">Applied Design</a></li> | <li><a href="https://2016.igem.org/Team:IISc_Bangalore/Design">Applied Design</a></li> | ||
− | </ul> | + | </ul> |
− | </li> | + | </li> |
</ul> | </ul> | ||
Line 137: | Line 139: | ||
<div class="content-middle wthree"> | <div class="content-middle wthree"> | ||
<div class="container" id="refer"> | <div class="container" id="refer"> | ||
− | + | <div class="mid-content fadeInRight wow animated" data-wow-delay=".5s"> | |
− | <h3> | + | <h3>Overview</h3> |
− | </div> | + | </div> |
+ | |||
<div class="row"> | <div class="row"> | ||
<div class="refer col-md-6"> | <div class="refer col-md-6"> | ||
+ | <p class="whitef">With the advent of rDNA technology in the late 1970s, medicine, agriculture and several other areas underwent a quantum leap and from that point, progress only hastened, from one only one recombinant pharmaceutical approved for human use (insulin) in 1982 to one hundred and fifty-one FDA approved protein based recombinant pharmaceuticals by 2009<a href="#refer" onclick="closeTab()">[1]</a>. | ||
+ | <br><a href="https://2016.igem.org/Team:IISc_Bangalore/Description"><span class="readm hvr-ripple-out">Read more</span></a> | ||
+ | </p> | ||
</div> | </div> | ||
</div> | </div> | ||
Line 147: | Line 153: | ||
</div> | </div> | ||
<!--content-middle--> | <!--content-middle--> | ||
− | < | + | <!--content-middle--> |
− | < | + | <div class="content-middle wthree"> |
− | < | + | <div class="container" id="refer"> |
− | </ | + | <div class="mid-content fadeInRight wow animated" data-wow-delay=".5s"> |
+ | <h3>Our Bioreactor Design</h3> | ||
+ | </div> | ||
+ | <div class="row"> | ||
+ | <div class="refer col-md-6"> | ||
<p class="whitef leftMove">We realized that manufacturing units use expensive and energy expensive machinery <a href="#refer" onclick="closeTab()">[3]</a>. Hence, we engineered our bacteria in such a way that it could do most of the work done by these monstrous machines so that we no longer have to buy them and pay their bills. | <p class="whitef leftMove">We realized that manufacturing units use expensive and energy expensive machinery <a href="#refer" onclick="closeTab()">[3]</a>. Hence, we engineered our bacteria in such a way that it could do most of the work done by these monstrous machines so that we no longer have to buy them and pay their bills. | ||
<br><a href="https://2016.igem.org/Team:IISc_Bangalore/Description"><span class="readm hvr-ripple-out">Read more</span></a> | <br><a href="https://2016.igem.org/Team:IISc_Bangalore/Description"><span class="readm hvr-ripple-out">Read more</span></a> | ||
</p> | </p> | ||
+ | </div> | ||
+ | </div> | ||
+ | </div> | ||
+ | </div> | ||
+ | <!--content-middle--> | ||
+ | |||
+ | |||
+ | |||
+ | |||
<br><br> | <br><br> | ||
Line 213: | Line 232: | ||
</div> | </div> | ||
</html> | </html> | ||
− | [[File: | + | [[File:Team3iisc.png|center|700px|From left: Abhijeet, Prabaha, Aiswarya, Shreyas, Arunavo, Srinath Sir]] |
<html> | <html> |
Latest revision as of 01:22, 20 October 2016
Overview
With the advent of rDNA technology in the late 1970s, medicine, agriculture and several other areas underwent a quantum leap and from that point, progress only hastened, from one only one recombinant pharmaceutical approved for human use (insulin) in 1982 to one hundred and fifty-one FDA approved protein based recombinant pharmaceuticals by 2009[1].
Read more